Oxford Genetics, a supplier of synthetic biology-based technologies for biologics discovery, development, and delivery, has secured a contract with a multi-billion dollar global e-commerce provider of reagents and tools to the research and clinical community.
As part of the agreement, Oxford Genetics will leverage its high throughput automated genomic engineering platform for CRISPR modification of mammalian cell lines.
The CRISPR system is capable of both functional knockout of genes and insertion of new sequences within genes as well as other manipulations of the genome, according to the company.
“We have moved away from manual processing, which is the norm in this market, in favor of automated, scalable platforms,” Ryan Cawood, CEO of Oxford Genetics, said. “This approach means we are well positioned to deliver the large number of custom-engineered cell lines per year that the global market is forecast to need.”
(Source: Oxford Genetics)
